What is the difference between analytical method validation, verification and transfer?

1Three questions, three kinds of evidence.

Each activity answers a different question about the same procedure, and each has its own source text.

2What validation requires.

US law requires that “the accuracy, sensitivity, specificity, and reproducibility of test methods employed by the firm shall be established and documented”.¹ Each laboratory record states the method used and where the data that establish it “meet proper standards of accuracy and reliability as applied to the product tested” can be found.² FDA defines analytical method validation as “the process of demonstrating that an analytical procedure is suitable for its intended purpose”. It expects validation data to be generated under a protocol approved by the sponsor, with predetermined and justified acceptance criteria, using qualified instrumentation.³

ICH Q2(R2) sets out which performance characteristics to study for each use and how: specificity, range, accuracy and precision, with robustness normally evaluated during development. A validation protocol comes before the study and a validation report after it.⁴ In the EU, Chapter 6 of the GMP guide states the principle in one line: “Testing methods should be validated.”⁵

3What verification requires.

Verification applies to a procedure someone else validated. Under 21 CFR 211.194(a)(2), a method in the current USP, National Formulary, AOAC Book of Methods or another recognised reference, or detailed in an approved new drug application and not modified, can be referenced by a statement of the method and its source. Even then, “The suitability of all testing methods used shall be verified under actual conditions of use.”²

FDA’s 2015 guidance says compendial methods “are verified rather than validated”. The verification protocol should include the compendial method with predetermined acceptance criteria and details such as reagents, equipment, chromatographic conditions, system suitability, sample preparation and stability. The extent of verification decides which characteristics are tested, for example specificity, detection and quantitation limits, precision or accuracy. Tighter specifications than the compendium, or a different synthetic route, process or matrix, can change what needs testing.³

The EU text is broader than compendial methods: “A laboratory that is using a testing method and which did not perform the original validation, should verify the appropriateness of the testing method.”⁵ A receiving laboratory that did not perform the original validation falls within that sentence too.

4What transfer requires.

EU GMP Chapter 6, in operation since 1 October 2014, has a section on technical transfer of testing methods.⁵

1. Before transfer, the transferring site verifies that the methods match the marketing authorisation, reviews the original validation against current ICH requirements, and documents a gap analysis to identify supplementary validation.
2. A detailed protocol describes the transfer. It identifies the testing and methods, additional training, the standards and samples to be tested, special transport and storage conditions, and acceptance criteria based on the current validation study.
3. Deviations from the protocol are investigated before the transfer closes.
4. The transfer report documents the comparative outcome and identifies areas that need further revalidation.

FDA treats transfer as a kind of analytical method comparability study. The originating and receiving laboratories run a preapproved protocol on the same lots, and the comparison evaluates accuracy and precision, especially interlaboratory variability. For a stability-indicating method, both sites should analyse forced degradation samples or samples containing relevant product-related impurities.³

ICH Q2(R2) and Q14 put transfer inside lifecycle change management. Transfer to another laboratory calls for partial or full revalidation, comparative analysis of representative samples, or both, or a justification for not doing more transfer experiments.⁴⁶ Co-validation, where several sites generate the validation data together, can also satisfy transfer at the participating sites.⁴

5Where the activities meet.

ICH Q14’s examples treat a transfer with no change to the procedure separately from a change to it. If the procedure changes within the same principle, the examples call for partial or full revalidation of the characteristics the change affects; if the principle itself changes, full validation of the new procedure.⁶ In the US, any modification of an established method must be recorded with its reason and data showing results “at least as accurate and reliable” as the original.² FDA also recommends keeping enough retention samples, including marketed product and, where possible, pivotal clinical trial material, to support these comparative studies.³

6How it runs in Seal.

In Seal’s analytical method lifecycle, validation, verification and transfer remain distinct assessments, and each laboratory’s readiness is assessed on its own evidence rather than inferred from the newest procedure version. A sending-lab study supports review without marking the method transferred, and the transfer package records the strategy, receiving-lab equipment, materials and trained analysts, local execution and discrepancies.

Neil, Seal’s AI agent, can prepare an analytical method transfer review: it compares sending- and receiving-laboratory evidence against the transfer protocol and exposes untested requirements. The transfer owner assesses comparability and QA approves the transfer report. For a contract testing laboratory, client-supplied, compendial and transferred methods each carry their ownership, approved version, site applicability and change-notification rules.